Ravi Srinivasan, i2o Therapeutics CEO

J&J and Sanofi-part­nered oral de­liv­ery biotech rais­es $26M on lat­est of­fer­ing

Ac­cord­ing to an SEC fil­ing Tues­day, i2o Ther­a­peu­tics raised $26 mil­lion in a pri­vate stock of­fer­ing.

The Har­vard spin­out start­ed out in April 2020 with $4 mil­lion in seed fund­ing led by Sanofi Ven­tures and JDRF T1D Fund. Then, less than a year lat­er, Sanofi re­turned for a part­ner­ship with i2o, cen­ter­ing around the oral de­liv­ery of nanobody-based drugs.

And ear­li­er this year, i2o inked an­oth­er big phar­ma pact — this time with J&J’s Janssen. But in­stead of nanobody-based drugs, the J&J col­lab­o­ra­tion fo­cus­es on the oral de­liv­ery of macro­mol­e­cules.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.